stem cells stable cell lines differentiated cells scalable bioprocessing engineered cell lines extracellular vesicles exosomes nanovesicles
Phoenestra is currently building end-to-end technology platforms to ensure highest technological and quality standards for our products - from donor sampling to released GMP-grade products.
NEW: EVscaleTM - Next Generation EV Manufacturing Platform
Our patented approach to use cells isolated from urine samples provides a non-invasive source for reprogramming somatic cells to induced pluripotent stem cells (iPSCs) from any healthy individual or specific patient, respectively. Selected iPS clones undergo a rigorous screening and characterization approach. Our iPS research cell banks fulfil all requirements for manufacturing of GMP-grade cell banks.
We are building our MSC technology platform on Evercyte´s industry-leading telomerized MSC lines derived e.g., from Bone Marrow, Adipose Tissue, Umbilical Cord, Wharton´s Jelly, Chorionic Plate or Amniotic Membrane. In contrast to primary MSCs, they maintain their phenotype and consistent growth properties over many generations. Depending on the selected donor and tissue of origin, these MSC lines and their extracellular vesicle preparations display promising biological activities for Regenerative Medicine applications.
The cell and gene therapy (CGT) field is currently still suffering from technological issues and rather low technological maturity levels. Phoenestra is committed to contribute to bridging the existing “industrialization gap” in CGT manufacturing technologies and products. This gap consists of technological pain points and sometimes prohibitive cost of manufacturing (CoM). Phoenestra is developing scalable processes including Control Strategies for cell- and vesicle-based products. The combination of stable, high quality cell lines and scalable bioprocesses with CMC Control Strategies will help bringing much needed products and therapies forward and, ultimately, help providing better access of patients in need to these innovative therapeutic modalities.
Based on our stem cell technology platforms, Phoenestra provides access to a wide variety of promising cell-based product candidates for R&D, drug discovery and therapeutic applications. From the start we have the requirements of the final product in mind.
The selection of donors and donor materials is performed with all safety, ethical and legal requirements in place. For iPS cell-derived products, Phoenestra is currently establishing an end-to-end approach from urine sampling to release of GMP-grade products. For MSC-based products, we provide a one-stop-shop concept in collaboration with Evercyte (stable cell lines, potency assays) and TAmiRNA, the expert company in RNA profiling and biomarker development.
EVscale™ is our world-leading technology platform for manufacturing biologically active EV with consistent quality and in clinically relevant quantities from small manufacturing footprints. With this tech platform, we are the ideal partner for your EV/exosome product development project. Please refer also to the EVscale™ Catalogue in the Resources section.
Interested? Please contact us for more details!
Products available and in preparation:
Phoenestra offers capabilities and resources also on a fee-for-service basis and dependent on your specific project needs. Please contact us for a discussion on options and opportunities for R&D work or a collaboration regarding GMP manufacturing services. Or simply send us your “Request for Proposal (RfP)”
R&D
GMP (please contact us for timelines)
For enquiries regarding our technology platforms, products and services, please contact
For any general inquiries or in case you are interested to join our team, please contact
phoenestra.com